

JAN 30 2004

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3	Attorney Docket Number	019934-004100US
-------	---	----	---	------------------------	-----------------


U.S. PATENT DOCUMENTS+						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
KAC	A1	US-5,141,867		08-25-1992	Ivanoff et al.	
	A2	US-5,705,151		01-06-1998	Dow et al.	
	A3	US-5,837,247		11-17-1998	Oppenheim et al.	
✓	A4	US-5,935,568		08-10-1999	Dow et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
KAC	B1	PCT	WO 94/28916	A1	12-22-1994	British Biotech Pharmaceuticals Limited		<input type="checkbox"/>
	B2	PCT	WO 96/11279	A2	04-18-1996	Government of the United States - Department of Health and Human Services		<input type="checkbox"/>
	B3	PCT	WO 96/36366	A1	11-21-1996	National Jewish Center for Immunology and Respiratory Medicine		<input type="checkbox"/>
	B4	PCT	WO 97/19696	A1	06-05-1997	Lusso, Paolo; Gallo, Robert C.; Cocchi, Fiorenza; DeVico, Anthony; Garzino-Demo, Alfredo		<input type="checkbox"/>
	B5	PCT	WO 98/15285	A1	04-16-1998	The Wistar Institute of Anatomy and Biology		<input type="checkbox"/>
	B6	PCT	WO 99/43839	A1	09-02-1999	Trustee of the University of Pennsylvania		<input type="checkbox"/>
	B7	PCT	WO 99/53960	A2	10-28-1999	Chiron Corp.		<input type="checkbox"/>
	B8	PCT	WO 00/22124	A2	04-20-2000	Canji, Inc.		<input type="checkbox"/>
✓	B9	PCT	WO 01/80882	A3	11-01-2001	ChemoCentryx, Inc.		<input type="checkbox"/>

Examiner Signature	<i>Karen J. Canella</i>	Date Considered	5/29/2004
--------------------	-------------------------	-----------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

60126179 v1




Substitute for form 1449B/PTO			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(use as many sheets as necessary)			
Sheet	2	of	3
			Attorney Docket Number
			019934-004100US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
KAC	C1	BANCHEREAU, JACQUES and RALPH M. STEINMAN; Dendritic cells and the control of immunity; <i>Nature</i> ; 19 March, 1998; pp. 245-252; Vol. 392	
	C2	CAUX, CHRISTOPHE, et al.; Developmental Pathways of Human Myeloid Dendritic Cells; <i>Dendritic Cells: Biology and Clinical Applications</i> ; 1999; pp. 63-92 (chapter 5); Academic Press	
	C3	ChemoTx Disposable; Neuro Probe website; Products (1 page) and Protocols (2 pages); Wednesday, April 19, 2000; <a href="http://www.neuroprobe">http://www.neuroprobe</a>	
	C4	CHOW, YEN-HUNG, et al.; Development of Th1 and Th2 Populations and the Nature of Immune Responses to Hepatitis B Virus DNA Vaccines Can Be Modulated by Codelivery of Various Cytokine Genes; <i>The Journal of Immunology</i> ; 1998; pp. 1320-1329; Vol 160	
	C5	DILLOO, DAGMAR, et al.; Combined chemokine and cytokine gene transfer enhances antitumor immunity; <i>Nature Medicine</i> ; October 1996; pp. 1090-1095; Vol. 2, No. 10	
	C6	ENG, VICKI M., et al.; The Stimulatory Effects of Interleukin (IL)-12 On Hematopoiesis Are Antagonized by IL-12-induced Interferon $\gamma$ In Vivo; <i>J. Exp. Med.</i> ; May 1995; pp. 1893-1898; Vol. 181	
	C7	EO, SEONG KUG, et al.; Modulation of immunity against Herpes Simplex Virus Infection via Mucosal Genetic Transfer of Plasmid DNA Encoding Chemokines; <i>Journal of Virology</i> ; January 2001; pp. 569-578; Vol. 75, No. 2	
	C8	GenBank Accession No. P27784, August 1, 1992	
	C9	KHUDYAKOV, YU E.; et al. Linear B-Cell Epitopes of the NS3-NS4-NS5 Proteins of the Hepatitis C. Virus as Modeled with Synthetic Peptides; <i>Virology</i> ; 1995; pp. 666-672; Vol 206	
	C10	LILJEQVIST, SISSELA & STÅHL, "Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines" <i>Journal of Biotechnology</i> , 1999, pp. 1-33, Vol. 73, Elsevier.	
	C11	MOLDOVEANU, ZINA, et al.; Immune responses induced by administration of encapsitated poliovirus replicons which express HIV-1 gag and envelope proteins; <i>Vaccine</i> ; 1995; pp. 1013-1022; Vol. 13, No. 11	
	C12	ORANGE, JORDAN S.; et al.; Mechanism of Interleukin 12-mediated Toxicities during Experimental Viral Infections: Role of Tumor Necrosis Factor and Glucocorticoids; <i>J. Exp. Med.</i> ; March 1995; pp. 901-914; Vol. 181	
	C13	R & D Systems 2000 Catalog; front and back cover, Contents in Brief, Ordering Information, (page i) Contact Information (page ii), Cytokines & Related Molecules (p. 93-94 and 162), Antibodies (p. 163-164 and 291)	
	C14	RAMSHAW, IAN; et al.; Expression of Cytokines by Recombinant Vaccinia Viruses: A Model for Studying Cytokines in Virus Infections <i>in vivo</i> ; <i>Immunological Reviews</i> ; 1992; pp. 157-182; No. 127	
✓	C15	TSUJI, T., et al.; HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine; <i>Immunology</i> ; 1997; pp. 1-6; Vol. 90	
Examiner Signature	<i>Karen A. Canella</i>		Date Considered 5/24/2004

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(use as many sheets as necessary)			
Sheet	3	of	3
		Complete if Known	
Application Number		10/001,221	
Filing Date		October 30, 2001	
First Named Inventor		Schall, Thomas J.	
Art Unit		1642	
Examiner Name		Canella, Karen A.	
Attorney Docket Number		019934-004100US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KAC	C16	WELLS, JAMES "Additivity of Mutational Effects in Proteins" <i>Biochemistry</i> , September 18, 1990; p. 8509-8517, Vol. 29, No. 37.	
	C17	WU, GEORGE Y., et al.; Receptor-mediated <i>in Vitro</i> Gene Transformation by a Soluble DNA Carrier System; <i>The Journal of Biological Chemistry</i> ; 1987; pp. 4429-4432; Vol. 262, No. 10	
✓	C18	XIANG, ZHIQUAN, et al.; Manipulation of the Immune Response to a Plasmid-Encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines; <i>Immunity</i> ; February 1995; pp. 129-135; Vol. 2	

Examiner Signature	<i>Karen A. Canella</i>	Date Considered	5/29/2009
--------------------	-------------------------	-----------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.